New hope for tough thyroid cancers: drug safety study shows promise
NCT ID NCT03573960
Summary
This study tested the safety and effectiveness of the drug lenvatinib in 50 patients with advanced thyroid cancer that had stopped responding to standard radioactive iodine treatment. Researchers monitored side effects and whether the drug helped control the cancer's growth. The goal was to gather real-world safety data on this already-approved medication for this specific group of patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
All India Institute of Medical Sciences
New Delhi, National Capital Territory of Delhi, 110029, India
-
All India Institute of Medical Sciences
Bhubaneshwar, Odisa, 751019, India
-
BL Kapoor Hospital, New Delhi
New Delhi, 110005, India
-
City Cancer Centre
Vijayawada, 520002, India
-
Deenanath Mangeshkar Hospital
Pune, Maharashtra, 411004, India
-
Indraprastha Apollo Hospital
New Delhi, National Capital Territory of Delhi, 110076, India
-
Indrayani Hospital, Alandi
Pune, 412105, India
-
Regional Cancer Centre, RCC, Thiruvananthapuram
Thiruvananthapuram, Kerala, 695011, India
-
S. P. Medical College & A. G. Hospitals
Bikaner, Rajasthan, 334003, India
-
Shetty's Hospital
Bangalore, Karnataka, 560068, India
-
Tata Memorial Hospital
Mumbai, 400012, India
Conditions
Explore the condition pages connected to this study.